Healthcare
Daiichi Sankyo Company, Limited(DSKYF)
Live Price
Offline$16.60
+2.72% today
1Y Change
-25.23%
Window
Jun 25, 2025 → Jun 18, 2026
- Market Cap
- $4.84T
- Revenue Growth
- +17.8%
- EPS Growth
- +49.0%
- Dividend Yield
- 3.0%
Coverage: 247 bars · Jun 25, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Daiichi Sankyo Company, Limited (DSKYF) is a Healthcare stock with a market cap of $4.84T and listed on OTC. The stock last traded around $16.60 and down 25.2% across the available one-year price window (Jun 25, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +17.8%, EPS growth of +49.0%, a dividend yield of 3.0%. What stands out right now is revenue +17.8%, EPS +49.0%, free cash flow -128.1% with operating margin 13.9% and ROIC 8.1%. The dividend matters to the case here, with a current yield around 3.0%. Valuation is more restrained than many high-expectation growth names at P/E 15.9 and price/sales 2.4. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines DSKYF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+17.8% vs +7.6% peer median
Operating Margin
Below sector median
+13.9% vs +19.4% peer median
P/E
Below sector median
15.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +17.8% and EPS at +49.0%, with operating margin around 13.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.0%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
DSKYF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DSKYF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DSKYF Max Drawdown
-48.58%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DSKYF and SPY.
Company Overview
Daiichi Sankyo Company, Limited
Other OTC
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
- Leadership
- Hiroyuki Okuzawa
- IPO Date
- Jun 24, 2008
- Employees
- 18.7k
- Street Address
- 3-5-1, Nihonbashi-honcho
- Mailing
- Tokyo, 103-8426
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 6225 1111
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 15.9
- EV/EBITDA
- 11.5
- Price/Sales
- 2.4
- Price/Book
- 2.8
Growth
- Revenue
- +17.8%
- EPS
- +49.0%
- Free Cash Flow
- -128.1%
Profitability
- Gross Margin
- 77.5%
- Operating Margin
- 13.9%
- Net Margin
- 14.8%
- ROE
- 18.6%
- ROIC
- 8.1%
Balance Sheet
- Debt/Equity
- 0.18
- Current Ratio
- 2.69
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.